Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $601.1 million.

  • Vanda Pharmaceuticals' Liabilities and Shareholders Equity fell 681.66% to $601.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year decrease of 321.77%. This contributed to the annual value of $656.2 million for FY2024, which is 119.73% up from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Liabilities and Shareholders Equity stood at $601.1 million, which was down 681.66% from $624.7 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Liabilities and Shareholders Equity peaked at $656.2 million during Q4 2024, and registered a low of $543.2 million during Q1 2021.
  • In the last 5 years, Vanda Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $631.9 million in 2025 and averaged $620.7 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Liabilities and Shareholders Equity soared by 1237.86% in 2021 and then tumbled by 681.66% in 2025.
  • Vanda Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $593.8 million in 2021, then increased by 6.81% to $634.2 million in 2022, then increased by 2.24% to $648.4 million in 2023, then increased by 1.2% to $656.2 million in 2024, then fell by 8.39% to $601.1 million in 2025.
  • Its last three reported values are $601.1 million in Q3 2025, $624.7 million for Q2 2025, and $631.9 million during Q1 2025.